Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000947 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 459
- Enrollment target
NCT02000947 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 459 participants.
The verdict
NCT02000947, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 459 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).
Interventions
- DRUG Tremelimumab
- DRUG MEDI4736
- DRUG tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2013-10-25 |
| Est. Completion | 2019-09-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02000947
The ClinicalTrials.gov registry entry for NCT02000947 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 459 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tremelimumab is the first listed.
NCT02000947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02000947 about?
NCT02000947 is a clinical study titled "A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer". The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).
What is the current status of trial NCT02000947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 459 participants. The study started on 2013-10-25. Estimated completion is 2019-09-17.
What interventions are being tested in trial NCT02000947?
The interventions under investigation include: Tremelimumab (DRUG), MEDI4736 (DRUG), tremelimumab (DRUG).
Who is sponsoring clinical trial NCT02000947?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.